论文部分内容阅读
目的研究干扰素加利巴韦林联合肝爽颗粒治疗丙肝肝硬化的疗效。方法将58例丙肝肝硬化患者随机分成治疗组和对照组各29例,两组均给予保肝对症等基础治疗,对照组给予干扰素加利巴韦林标准治疗48周,治疗组给予干扰素加利巴韦林联合肝爽颗粒治疗48周,停后观察24周。结果在观察治疗结束时治疗组ALT为(24.3±10.5)U/L,AST为(22.5±14.1)U/L,ALB(37.1±2.1)g/L,TBIL(27.4±9.8)ummol/L。其改善程度显著优于对照组(P均<0.01),血清肝纤维化指标下降情况明显优于对照组,门脉宽度及脾厚缩小明显优于对照组。两组HCVRNA的转阴率和SVR率无显著性差异。结论肝爽颗粒联合干扰素加利巴韦林治疗丙肝肝硬化具有显著的临床疗效。
Objective To study the efficacy of interferon plus ribavirin combined with Gan Shuang granules in the treatment of hepatitis C cirrhosis. Methods Fifty-eight patients with hepatitis C cirrhosis were randomly divided into treatment group and control group, with 29 cases in each group. Both groups were given basic treatment of liver protection and symptomatic treatment. The control group was treated with interferon plus ribavirin for 48 weeks. The treatment group received interferon Ribavirin plus ribavirin combined treatment for 48 weeks, after stopping for 24 weeks. Results The ALT in the treatment group was (24.3 ± 10.5) U / L, (22.5 ± 14.1) U / L, ALB (37.1 ± 2.1) g / L and TBIL (27.4 ± 9.8) ummol / L at the end of the observation period. The improvement was significantly better than that of the control group (P <0.01). The decrease of serum hepatic fibrosis index was significantly better than that of the control group. The width of the portal vein and splenomegaly decreased significantly better than that of the control group. There was no significant difference between the two groups in HCV RNA conversion rate and SVR rate. Conclusion Gan Shuang granules combined with interferon plus ribavirin in the treatment of hepatitis C cirrhosis has a significant clinical effect.